JAGSNPHARM.BO(JAGSNPHARM.BO)

$186.20▲1.35 (73.03%)

JAGSNPHARM.BO(JAGSNPHARM.BO)

BSE

$186.20▲1.35 (73.03%)

Revenue (LTM)

$2.7B

+28.8% YoY

Net Income (LTM)

$554M

+146.5% YoY

Free Cash Flow

$550M

Revenue CAGR (5Y)

+9.4%

Marginsdeclining

FCF$0.5B

Profitable

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Revenue	1,879	2,176↑15.8%	2,367↑8.8%	2,087↓11.8%	2,687↑28.8%
Gross Profit	1,069	1,283↑20.0%	1,436↑11.9%	653↓54.6%	1,723↑164.0%
Operating Income	188	245↑30.7%	343↑39.9%	214↓37.7%	435↑103.5%
Net Income	171	189↑10.5%	267↑41.7%	225↓15.9%	554↑146.5%
EBITDA	235	285↑21.2%	364↑27.9%	323↓11.1%	511↑57.9%
EPS Diluted	2.60	2.88↑10.8%	4.08↑41.7%	3.39↓16.9%	8.22↑142.5%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Cash & Equivalents	619	251↓59.4%	111↓56.0%	128↑15.4%	1,287↑908.9%
Total Current Assets	1,205	1,091↓9.5%	1,646↑50.9%	1,993↑21.1%	1,612↓19.1%
Total Assets	1,642	1,685↑2.6%	1,949↑15.7%	2,171↑11.4%	2,783↑28.2%
Total Current Liabilities	404	270↓33.2%	276↑2.2%	191↓30.6%	259↑35.4%
Total Liabilities	423	376↓11.1%	361↓4.1%	297↓17.7%	383↑29.1%
Total Equity	1,219	1,309↑7.3%	1,589↑21.4%	1,874↑17.9%	2,400↑28.0%
Total Debt	68	52↓22.7%	60↑14.4%	89↑49.0%	92↑3.3%
Net Debt	-551	-251↑54.4%	-51↑79.9%	-38↑24.4%	-1,195↓3028.9%

Metric	Mar 21	Mar 22	Mar 23	Mar 24	Mar 25
Operating Cash Flow	282	69↓75.5%	467↑574.8%	352↓24.6%	553↑57.3%
Capital Expenditure	-5	-5↑0.3%	-3↑32.1%	-2↑21.9%	-3↓40.3%
Free Cash Flow	278	51↓81.5%	463↑803.1%	349↓24.6%	550↑57.4%
Stock-Based Comp	0	0	88	133↑51.9%	68↓48.9%
Net Change in Cash	191	-364↓290.4%	-115↑68.5%	17↑114.9%	-15↓190.5%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance